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Edited by Irmgard SinningAbstract We assessed the eﬀect of multiple-mutations within
one IgE-binding area on allergenicity of Der f 2. The triple-
mutant of Der f 2, P34/95/99A, exhibited the most signiﬁcant
reduction of allergenicity and circular dichroism analysis showed
that the global structure of Der f 2 was maintained in P34/95/
99A. These results indicate that such a strategy is eﬀective when
designing allergen-vaccines, which achieve less allergenicity for a
broad population of patients without disrupting the global struc-
ture. Structurally, Der f 2 is a member of the MD-2 related lipid-
recognition proteins. The sites for the triple-mutation located on
the characteristically charged entrance of a cavity and corre-
sponded to the regions critical to ligand-binding in the Nie-
mann-Pick type 2 disease protein and MD-2.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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House dust mites of two species of Dermatophagoides (Der-
matophagoides farinae and Dermatophagoides pteronyssinus)
associated with various allergic diseases such as bronchial asth-
ma, rhinitis, and atopic dermatitis are the most important
source of in-door allergens [1]. Group 1 (Der f 1 and Der p
1) and group 2 (Der f 2 and Der p 2) allergens derived from
house dust mites are considered major allergens based on the
frequency of patients sensitized, amount of speciﬁc IgE, and
content in mite extract [2].
Der f 2 from D. farinae [3] consists of 129 amino acid resi-
dues. Its IgE epitopes are dependent on the integrity of theAbbreviations: CD, circular dichroism; LPS, lipopolysaccharide;
NPC2, Niemann-Pick type 2 disease; PVDF, polyvinylidene diﬂuoride;
RAST-EIA, radioallergosorbent test-enzyme immunoassay; SDS–
PAGE, sodium dodecyl sulphate–polyacrylamide gel electrophoresis;
TBS, Tris-buﬀered saline; ELISA, enzyme-linked immunosorbent
assay
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of amino acids [4–7]. The amino acid sequence of Der f 2 is
homologous to other group 2 allergens from diﬀerent mite spe-
cies and the Niemann-Pick type C2 disease protein (NPC2/
HE1) with cholesterol-binding activity [8–10]. Recently, a
structural relationship between the Der f 2 homologues and
MD-2, which associates with Toll-like receptor 4 on the cell
surface and is part of the mammalian innate immune system
involved in the recognition of lipopolysaccharide (LPS) from
gram-negative bacteria [11], was indicated by a PSI-BLAST
search [12]. Although NPC2 and MD-2 bind cholesterol [13]
and LPS [14], respectively, the ligand(s) for the mite group 2
allergens has not been identiﬁed.
Mutant allergens with reduced binding to IgEwould be useful
for a safer and more eﬀective allergen-speciﬁc immunotherapy
[15]. The mutation of residues contributing to a key intramolec-
ular interaction of allergen molecules would be an eﬀective and
widely applicable way to reduce allergenicity [6,7]. Another
strategy is to introduce mutations at the molecular surface with-
out disrupting the global structure. To eﬀectively induce the pro-
duction of blocking antibodies, a mutant allergen with a nearly
intact global structure would have an advantage over one with
disruption of global structure [16,17].
In this report, we assess the eﬀect of multiple-mutations in
one IgE-binding area, which do not cause a disruption of the
global structure, on IgE-binding and basophil histamine-
releasing activity using recombinant Der f 2 as a model
allergen. We chose Pro95, Pro99, and Pro34, which are close
together at one end of the tertiary structure and contribute
to IgE-binding [18], as target residues for the double- and tri-
ple-mutations. We suggest that such a strategy is also eﬀective
when designing allergen-vaccines less allergenic for a wide pop-
ulation of patients without disruption of the global structure.
Furthermore, we indicate colocalization of this IgE-binding
area and the potential ligand-binding region of Der f 2 on
the basis of the 3D structure.2. Materials and methods
2.1. Cloning of cDNA coding for Der f 2
Total RNA was prepared from cultured mites, and the cDNA frag-
ments of Der f 2 were synthesized, ampliﬁed by reverse transcription-
polymerase chain reaction, subcloned into vectors and sequenced as
described previously [19].blished by Elsevier B.V. All rights reserved.
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The cDNA encoding the amino acid sequence of an isoform of
wild-type Der f 2, which was designated as clone 11/Der f 2.0103
[3,20] and identical to the clone used in our previous mutational anal-
yses [4–7,18], was subcloned into an expression vector, a modiﬁed
pGEMEX-1 (Promega, Madison, WI). Expression vectors for mu-
tants of Der f 2 were constructed by site-directed mutagenesis. The
wild-type Der f 2 and its mutants were expressed in Escherichia coli,
refolded, and puriﬁed as described previously [18]. The protein con-
centration was calculated based on the absorbance at 280 nm and
the number of tyrosine and tryptophan residues in Der f 2.
2.3. Gel-ﬁltration analysis
Gel-ﬁltration analysis was performed as previously described [18]
with some modiﬁcations. Brieﬂy, puriﬁed recombinant allergens
(0.1 ml, approximately 0.1 mg/ml) were subjected to gel-ﬁltration chro-
matography on a Superdex 75 HR 10/30 (1 cm · 30 cm) (Amersham
Biosciences, Piscataway, NJ, USA) at a ﬂow rate of 0.5 ml/min with
50 mM Tris–Cl (pH 7.5) containing 150 mM NaCl and 0.01% sodium
azide. Apparent molecular sizes of the recombinant allergens were esti-
mated using standard proteins.
2.4. Circular dichroism
Circular dichroism (CD) spectra were measured on a JASCO J-820
spectropolarimeter (Japan Spectroscopic Co., Ltd., Tokyo, Japan)
using a 0.1-cm cell at 25 C over 190–260 nm. Samples at 0.1 mg/ml
were dialyzed against 10 mM potassium phosphate buﬀer (pH 7.5).
The experimental parameters were: bandwidth 1.0 nm, sensitivity 100
millidegrees, step resolution 0.5 nm/datum, scan speed 50 nm/min,
and scans 10.
2.5. Dot blot analysis
The sera were obtained from mite sensitive atopic patients with
bronchial asthma, allergic rhinitis, and/or atopic dermatitis who
proved positive to a skin prick test. Puriﬁed recombinant proteins
(500 ng of protein/0.1 ml of Tris-buﬀered saline [TBS]/dot) were immo-
bilized onto a polyvinylidene diﬂuoride (PVDF) membrane (Immobi-
lon-P; Millipore, Billerica, MA, USA) using a blotting apparatus
(Bio-Dot; Bio-Rad, Heracles, CA, USA) according to the manufac-
turers instructions. The membrane was blocked with BlockAce (Snow
Brand, Sapporo, Japan) (diluted 1/4 with TBS and 0.05% Tween 20) at
room temperature for 1 h, and then, incubated with mite-allergic pa-
tient sera (1/100) for 3 h. After being washed three times with TBS
and 0.05% Tween 20, the membrane was incubated with peroxidase-
conjugated anti-human IgE antibody (Biosource, Camarillo, CA,
USA) (1/1000) for 1.5 h. After being washed again, the membrane
was developed with an ECL+ kit (Amersham Biosciences). The chemi-
luminescence was detected with an LAS-1000 (Fuji Film, Tokyo, Ja-
pan). The density of the dots was calculated using the computer
software ImageGauge V4.0 (Fuji Film). Group data were statistically
analyzed with Prism version 4.0 (GraphPad, San Diego, CA, USA).
2.6. Radioallergosorbent test-enzyme immunoassay
IgE reactivities were measured by radioallergosorbent test-enzyme
immunoassay (RAST-EIA) as previously described [5]. Brieﬂy, the di-
luted serum of each allergic patient was incubated with paper discs
coupled with the allergens. Then, the IgE that bound to the disc was
detected with b-galactosidase-conjugated anti-human IgE antibodies
by measuring the ﬂuorescence.
2.7. Inhibition assay
The method used was described previously [7]. Brieﬂy, the diluted
serum of each mite-allergic patient was incubated with various concen-
trations of each inhibitor recombinant protein and then the solution
was added to a paper disc coupled covalently with wild-type Der f
2.The IgE that bound to the discs was detected with b-galactosidase-
conjugated anti-human IgE antibodies. The percentage of inhibition
was expressed as the relative reduction of the ﬂuorescence intensity
in each sample to that when no inhibitors were added.
2.8. Histamine release
The method employed was as described [21] using HRT-Shionogi
(Shionogi and Co., Ltd., Osaka, Japan) with some modiﬁcations.
Brieﬂy, basophil-containing leukocytes were directly puriﬁed from asmall amount of peripheral blood using magnetic beads coated with
a monoclonal antibody. The cell–bead complexes on the magnetic de-
vice were then transferred to another microplate, which was coated
with streptavidin for enzyme-linked immunosorbent assay (ELISA)
and contained allergen solution. After the incubation, the cell–bead
complexes on the magnetic device were removed and the histamine
content was measured by ELISA. The amount of histamine released
after incubation with 0.2 mg/ml of digitonin was used as the total his-
tamine content for the calculation. The percentage of histamine re-
leased was calculated as the relative amount of histamine in the
supernatant to the total amount of histamine.
2.9. Molecular modeling
Homology models of wild-type Der f 2 clone 11/Der f 2.0103 and its
triple-mutant P34/95/99A were both generated using the program
MODELLER [22] release 6v2, starting from the reﬁned structure of
Der f 2 clone 1/Der f 2.0101 [23], without large steric hindrance. The gra-
phicwas produced using the programsMolscript [24] andRaster3D [25].3. Results
3.1. Expression and puriﬁcation of single- and multiple-proline
mutants of Der f 2
Der f 2 has no N-glycosylation site in the deduced amino
acid sequence, and the recombinant Der f 2 with an additional
methionine at the ﬁrst N-terminal residue showed the mobility
on sodium dodecyl sulphate–polyacrylamide gel electrophore-
sis (SDS–PAGE) and secondary structure identical to the nat-
ural Der f 2 puriﬁed from mite extract (data not shown). The
wild-type, three single-mutants (P34A, P95A, and P99A), three
double-mutants (P34/95A, P34/99A, and P95/99A), and a tri-
ple-mutant (P34/95/99A) of Der f 2 were overexpressed as
insoluble inclusion bodies in E. coli cells. The proline was re-
placed by an alanine residue in these mutants. Each of the re-
folded and puriﬁed proteins was detected as a single band on
SDS–PAGE (Fig. 1A). Mobilities of the wild-type and all mu-
tants of Der f 2 were almost equivalent to each other.
3.2. Secondary structures of single- and multiple-proline mutants
of Der f 2
Each additional proline mutation caused a small change in
the CD spectrum (Fig. 1B). The single-mutants showed small
diﬀerences from the wild-type Der f 2. The double-mutants
showed small diﬀerences from the progenitor single-mutants.
The triple-mutant P34/95/99A showed a small diﬀerence from
the double-mutants. However, as the diﬀerences were small, it
was suggested that the structural changes were local and that
the global b-sheet structure of Der f 2 was maintained. Muta-
tion of Pro95 to alanine increased the ellipticity at 220–235 nm
(Fig. 1B, the upper panel) in P95A, P34/95A, P95/99A, and
P34/95/99A.3.3. Estimation of molecular sizes by gel-ﬁltration analysis
The puriﬁed wild-type Der f 2 and the triple-mutant P34/95/
99A were detected as a single peak in gel-ﬁltration analysis,
and their apparent molecular weights were 14 and 15 kDa,
respectively (Fig. 2). This also suggested that the global struc-
ture of Der f 2 was maintained.
3.4. Direct IgE-binding and inhibitory activity of single- and
multiple-proline mutants of Der f 2
The reactivity of IgE to the puriﬁed Der f 2 mutants immo-
bilized on a PVDF membrane was examined by dot blot
Fig. 1. Puriﬁcation of single- and multiple-proline mutants of Der f 2.
(A) SDS–PAGE (10–20% acrylamide) under reducing conditions. The
gel was stained with Coomassie brilliant blue. WT, recombinant wild-
type Der f 2. M, molecular weight marker. (B) Circular dichroism.
Upper panel: spectra of mutants with P95A mutation. Lower panel:
spectra of mutants without P95A mutation.
Fig. 2. Elution proﬁles in gel-ﬁltration analysis of puriﬁed wild-type
Der f 2 and the triple-mutant P34/95/99A. The apparent molecular
weights of the peaks are shown with an arrow.
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reduced IgE-binding compared to the wild-type Der f 2. The
double-mutants showed reduced or equivalent IgE-binding
compared to the progenitor single-mutants. By the Tukey post
hoc test following with the repeated measures ANOVA, the tri-
ple-mutant P34/95/99A showed signiﬁcantly lower binding
than the other mutants except P95/99A (Fig. 3C). By the
paired t test (two-tailed), P34/95/99A showed signiﬁcantlylower binding than P95/99A (P = 0.0027). These results sug-
gested that additional mutations decreased the total avidity
of the mutants to the polyclonal IgE antibodies. The pattern
of IgE reactivity to the mutants was not always similar among
patients (Fig. 3B), suggesting that the contribution of the three
proline residues to IgE-binding was not the same for all
patients.
Using paper discs covalently coupled with the wild-type or
mutants of Der f 2, the reactivity of IgE to the Der f 2 mutants
(Fig. 4A) and the capacity of the mutants to inhibit IgE from
binding to the immobilized wild-type Der f 2 (Fig. 4B) were
examined. The triple-mutant P34/95/99A showed the lowest
levels of binding and inhibitory activity.
3.5. Activity of single- and triple-mutants of Der f 2 in
stimulating histamine release by basophils
Peripheral blood basophils from mite-allergic volunteers
were stimulated with the wild-type, single-mutants, and tri-
ple-mutant of Der f 2, and histamine release was measured
(Fig. 5). The pattern of histamine-releasing activity of the sin-
gle-mutants diﬀered among the volunteers. The triple-mutant
P34/95/99A showed the lowest activity in all volunteers tested.
Threshold concentrations of the triple-mutant necessary for
histamine release were approximately 10-fold higher in Volun-
teers #12 and #13, and 4–6-fold higher in #14 than those of
the wild-type Der f 2.
3.6. Characteristic features of the region surrounding Pro 95,
Pro99, and Pro34 on the modeled structure
To obtain information on the structural background of the
signiﬁcant reduction of allergenicity of the triple-mutant P34/
95/99A, we investigated the features of the region surrounding
the sites for the triple-mutation on the basis of a 3D model
based on the nuclear magnetic resonance structure of Der f 2
[23,26]. Interestingly, the three proline residues located on
the characteristically charged molecular surface, where seven
charged residue and the charged C-terminal carboxyl group
existed (Arg31, Lys33, Lys96, Lys100, Lys126, Arg128, and
Asp129), at one edge of the entrance of a cavity (Fig. 6A,
top). As the cavity of Der f 2 was expected to be involved in
interaction with the unknown ligand, locations of amino acid
residues critical to cholesterol-binding in NPC2 [27] and
Fig. 3. Dot blot analysis of IgE-binding of single- and multiple-proline mutants of Der f 2. Density of the dots shown in A was measured and the
calculated values are shown in B. (C) Data shown represent the means ± S.E.M. of the 12 sera. Multiple comparison by the Tukey post hoc test
following with the repeated measures ANOVA showed all combinations except those indicated are signiﬁcantly diﬀerent each other (P < 0.05). ns:
not signiﬁcantly diﬀerent (P > 0.05). WT, wild-type Der f 2.
T. Nakazawa et al. / FEBS Letters 579 (2005) 1988–1994 1991cellular LPS-recognition in MD-2 [28–31] were compared with
the location of the triple-mutation of P34/95/99A in Der f 2
(Fig. 6B and C). To our surprise, the loop containing Pro95
and Pro99 of Der f 2 corresponded to the regions critical to
the ligand-binding in NPC2 and MD-2 (Fig. 6B). The residue
Gly59 of mouse MD-2 corresponding to the residue next to
Pro34 of Der f 2 is also involved in LPS-recognition (Fig. 6C).4. Discussion
The target residues, Pro95, Pro99, and Pro34, are closely lo-
cated in loops at one end of the tertiary structure (Fig. 6A),
which we previously suggested that these residues compose a
single IgE-binding area [18]. The patterns of IgE-binding
capacity (Figs. 3B and 4) and histamine-releasing activity
(Fig. 5) of the mutants were not always similar among patients
suggesting that the contribution of each of the three proline
residues to allergenicity was not the same for all patients.
We have demonstrated that allergenicity of the triple-mutant
of Der f 2, P34/95/99A, most signiﬁcantly decreased for all pa-tients tested while that of the single- or double-mutants did not
decrease for all (Figs. 3–5). The triple-mutant showed a de-
crease in anaphylactic potential, because histamine release
from human basophils was reduced (Fig. 5). The secondary
structure (Fig. 1B) and molecular compactness (Fig. 2) are al-
most identical between wild-type Der f 2 and P34/95/99A.
Therefore, the reduction of allergenicity of P34/95/99A was
not accompanied by a disruption of global structure. These re-
sults suggest that multiple-mutation within one IgE-binding
area is eﬀective when designing allergen-vaccines, which
achieve hypoallergenicity for a broad population without dis-
rupting global structure, for allergen-speciﬁc immunotherapy.
The binding and inhibitory activity, which was assayed in
individual tubes for the triple-mutant P34/95/99A, was at rela-
tively signiﬁcant levels for some sera (Fig. 4) compared with
much less direct IgE-binding of the triple-mutant than the
wild-type Der f 2, which was assayed in a same plastic bag
for all the recombinant proteins dotted onto a PVDF mem-
brane (Fig. 3). Threshold concentrations of the triple-mutant
necessary for histamine release were 4–10-fold higher than
those of the wild-type Der f 2 (Fig. 5). These results suggest
A B
Fig. 4. Direct IgE-binding (A) and inhibitory activity (B) of single- and
triple- mutants of Der f 2. The serum dilution was 1/8 for #10–12, 1/4
for #13, and 1/100 for #14. The allergen concentration in the
immobilization step was 25 nM for #11 and #14, 50 nM for #10 and
#13, and 90 nM for #12 in A, and 100 nM except for #12 (20 nM) in B.
WT, wild-type Der f 2.
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Fig. 5. Activities of single- and triple-mutants of Der f 2 to induce
histamine release from basophils.The percentage of histamine released
was calculated as the relative amount of histamine in the supernatant
to the total amount of histamine. Spontaneous histamine release
without stimulation by allergens in Volunteers #12, #13, and #14 was
7.5%, 2.0%, and 20.1%, respectively. The results shown are represen-
tative of two or three independent experiments. WT, wild-type Der f 2.
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epitopes for some sera although its aﬃnity is lower than the
wild-type Der f 2. Disparities between the direct IgE-binding
and inhibition experiments for Serum #14 (Fig. 4, #14) might
be attributed to that the inhibition assay was performed in the
experimental conditions where only 30% inhibition by thewild-type Der f 2 was observed in Serum #14 (Fig. 4B, #14)
while 65–90% inhibition was observed in the other sera (Fig.
4, #10–13). The Der f 2-speciﬁc IgE titer of Serum #14 was
very high and more extensive dilution (1/100 dilution) than
other sera (1/3–1/8 dilution) was needed to detect even this le-
vel of inhibition. Further dilution of Serum #14 and/or in-
crease of the inhibitor concentration might be necessary for
detection of more signiﬁcant inhibition by the triple-mutant.
Mutant allergens with reduced binding to IgE would be use-
ful for a safer and more eﬀective allergen-speciﬁc immunother-
apy [15]. Previously, we proposed that the mutation of residues
contributing to key intramolecular interactions to maintain the
global structure of an allergen would be an eﬀective strategy to
reduce allergenicity [7]. A mutant Der f 2, C8/119S, which
lacks a disulﬁde bond showed markedly reduced allergenic
activities, maintained T-cell epitopes, induced Th1 rather than
Th2 cytokine production and had hyposensitizing activities
when administered to Der f 2-sensitized mice [6,7,32,33]. The
compactness of the global structure was disrupted in this mu-
tant [7]. On the other hand, it has been suggested that blocking
antibodies belonging to a subclasses other than IgE contribute
to the eﬃcacy of allergen-speciﬁc immunotherapy [16,34]. The
beneﬁcial eﬀect of the blocking antibodies is considered to
arise from an impairment of allergic symptoms caused by
blocking IgE from binding the allergen, modulating antigen-
presentation through the uptake of allergen to antigen-present-
ing cells through Fc receptors, and/or downregulation of signal
transduction through an Fcc receptor with an inhibition motif.
P34/95/99A with a nearly intact global structure might have an
advantage in inducing the blocking antibodies. Fig. 6A shows
that P34/95/99A modiﬁed only a small area of the molecular
surface, and the surrounding unchanged areas would induce
an IgG fraction that sterically hinders even the binding of
P34/95/99 to IgE. Very recently, two mutants of birch pollen
Fig. 6. Characteristic features of the region surrounding the triple-
mutation P34/95/99A of Der f 2. (A) The color changes from blue (N-
terminus) to red (C-terminus). The charged residues close to the
mutations are shown as blue (positive) and red (negative) wires. (B and
C) Sequence alignment of Der f 2, NPC2, and MD-2 including the
triple-mutation. Blue residues in B and C have been reported to be
involved in ligand-recognition.
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cept of reduction of IgE-binding without disruption of global
structure has been reported, although four or nine amino acid
substitutions were introduced into three or ﬁve diﬀerent areas
on the molecular surface in the two Bet v 1 mutants, respec-
tively [17], diﬀering from the Der f 2 mutant, P34/95/99A, in
which three substitutions were introduced into one area.
Although prolines undergo cis/trans isomerization, and
depending on the local topology, can induce drastic changes
in the secondary and tertiary structure of a protein, the multi-
ple-mutants of Der f 2 retained the global structure. This might
be attributable to that the three prolines are positioned on a
loop on the top of the molecule and not within structurally
essential regions to form a helices or b sheets (Fig. 6A). We
consider that the small diﬀerences between wild-type Der f 2
and P34/95/99A in secondary structure (Fig. 1B) and apparentmolecular compactness (Fig. 2) are due to local structural
change. The spatial relationship of Pro95 and Try92 is appro-
priate for non-conventional C–H. . .p interaction [35], so the
small change in CD spectra at 220–235 nm on P95A mutation
might be due to the loss of this interaction. The change in the
apparent molecular compactness suggests a fast equilibrium
with a partially unfolded state. The ﬁrst candidate for the
unfolding site would be the loop containing Pro95 and
Pro99, whose substitutions with alanine residues would have
further increased the ﬂexibility of the loop.
The target residues for the triple-mutation to achieve the sig-
niﬁcant reduction in allergenicity were revealed to be located
on the characteristically charged molecular surface at the edge
of the entrance of a potential ligand-binding cavity (Fig. 6A)
and to correspond to the region essential to ligand-recognition
in NPC2 and MD-2 (Fig. 6B and C). Such a cavity is also re-
ported in the crystal structures of another mite group 2 aller-
gen Der p 2 [36] and a mammalian cholesterol binding
protein NPC2 [37], which are homologous to Der f 2. These
experimental results and structural information are interesting
when considering the relation between the ligand-binding
structure and IgE-binding structure. The experimental results
suggest this region is, at least, one of the major IgE-binding
areas on the molecular surface of Der f 2. Such a characteristic
combination of charge distribution, ﬂexibility and proximity to
the hydrophobic cleft is generally preferably recognized both
by low-molecular ligands and by proteins. But whether other
speciﬁc mechanisms are involved during sensitization processes
in the background of this colocalization of a major IgE-bind-
ing area and the region potentially essential to ligand-recogni-
tion is still unknown.
In summary, we assessed the eﬀect of multiple-mutations in
one IgE-binding region, which do not cause a disruption of the
global structure, on allergenicity using recombinant Der f 2 as
a model allergen and suggested that such strategy is eﬀective.
Furthermore, we showed colocalization of a major IgE-bind-
ing area and the potential ligand-binding region of Der f 2
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